Dianthus Therapeutics, Inc.

NASDAQ:DNTH

Biotechnology

Healthcare
$83.98 -1.25%

-$1.03 today

Market cap
$4.73B
Beta
0.07
P/E (TTM)
-343.0
EPS (TTM)
-$0.24
52W Low $16.64High $96.50

Volume 0.84M

Average 0.82M

DNTH Weighted Avg Shares (Diluted)

Average shares outstanding including dilutive securities, used to calculate diluted EPS.

Dianthus Therapeutics, Inc.NASDAQ: DNTH

Weighted Avg Shares (Diluted) · Q2 FY2026 · quarter ended Jun 2026

Weighted avg shares (diluted) growth accelerates

Q2 FY2026 weighted avg shares (diluted) of 56.03M shares rose 56.4% year over year, ahead of the +27.5% change in trailing-twelve-month weighted avg shares (diluted). Sequentially, it rose 16.6% from the prior quarter. Over 3 fiscal years it compounded at +116.1% a year.

Context

  • Weighted avg shares (diluted) increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of +56.4% holds above the trailing-twelve-month pace of +27.5%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterJun 2026
56.03M+16.6% QoQ
Last fiscal yearDec 2025
37.79M+13.4% YoY
LTMJun 2026
44.91M+27.5% YoY
Weighted Avg Shares (Diluted) past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+56.4%——
1 year+13.4%——
3-year CAGR+116.1%——
5-year CAGR——
10-year CAGR——

Weighted Avg Shares (Diluted) history

Shares · from the income statement

Latest · FY2025
37.79M USD
Year-over-year change
+13.4%
4-year CAGR
+82.1%

Weighted Avg Shares (Diluted) vs competitors

How DNTH compares with its peers on the latest reported figures

  • DNTH's LTM Jun 2026 weighted avg shares (diluted) of 44.91M shares is the 6th highest of the 10 companies compared; the peer median is 55.66M shares.
  • Its year-over-year change of +27.5% is the 2nd highest of 10, against a peer median of +5.6%.
  • Over three fiscal years its annual growth of +116.1% compares with a peer median of +30.0%.
DNTH Competitors Peer median
Weighted Avg Shares (Diluted) for DNTH and competitors
Company Period LTM YoY 3-year CAGR
IMVTImmunovant, Inc.LTM Sep 2026199.36M +24.0%+14.0%
ALMSAlumis Inc. Common StockLTM Jun 2026115.39M +93.6%+384.0%
VERAVera Therapeutics, Inc.LTM Jun 202667.85M +14.4%+34.2%
MLTXMoonLake ImmunotherapeuticsLTM Mar 202665.6M +4.1%+30.0%
CNTBConnect Biopharma Holdings LimitedFY202555.66M +0.8%+0.4%
DNTHDianthus Therapeutics, Inc.LTM Jun 202644.91M +27.5%+116.1%
ANABAnaptysBio, Inc.LTM Mar 202629.47M +0.4%+3.6%
RNACCartesian Therapeutics, Inc.LTM Mar 202626.32M +15.6%+85.8%
ARTVArtiva Biotherapeutics, Inc.LTM Mar 202624.5M +1.8%+11.6%
QTTBQ32 Bio Inc.LTM Mar 202612.78M +5.6%+56.9%
Peer median (excluding DNTH) 55.66M+5.6%+30.0%

Competitors are the stored peer set for DNTH. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue1.48M6.42M2.83M6.24M2.04M
Cost of Revenue00000
Gross Profit1.48M6.42M2.83M6.24M2.04M
Gross Margin100.0%100.0%100.0%100.0%100.0%
Research & Development12.61M29.38M32.84M83.11M145.64M
Selling, General & Admin1.96M6.74M18.16M24.99M34.33M
Operating Expenses14.56M36.12M51M108.1M179.97M
Depreciation & Amortization2.02M147K355K412K428K
EBITDA(11.09M)(28.33M)(43.2M)(84.56M)(161.91M)
EBITDA Margin-751.3%-441.5%-1528.7%-1356.2%-7952.3%
Operating Income(13.09M)(29.71M)(48.17M)(101.86M)(177.93M)
Operating Margin-886.6%-462.9%-1704.7%-1633.7%-8739.3%
Interest Income100K1.15M4.76M17.37M16.12M
Interest Expense00000
Other Income / Expenses(23K)1.23M4.62M16.9M15.6M
Income Before Tax(13.11M)(28.48M)(43.56M)(84.97M)(162.34M)
Pre-Tax Margin-888.1%-443.8%-1541.2%-1362.8%-7973.3%
Income Tax Expense00000
Net Income(13.11M)(28.48M)(43.56M)(84.97M)(162.34M)
Net Margin-888.1%-443.8%-1541.2%-1362.8%-7973.3%
EPS (Basic)(3.82)(7.60)(8.45)(2.55)(4.20)
EPS (Diluted)(3.82)(7.60)(8.45)(2.55)(4.20)
Weighted Avg Shares3.43M3.75M5.15M33.31M37.79M
Weighted Avg Shares (Diluted)3.43M3.75M5.15M33.31M37.79M

Dianthus Therapeutics, Inc.

NASDAQ:DNTH

Intrinsic Alpha fair value

Locked

Current Price

$83.98

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.